Whitney R. Redding

Whitney concentrates her practice in commercial litigation, with a particular focus on securities class action litigation, domestic and international arbitration, appellate matters, and complex breach of contract disputes. She represents Fortune 500 companies, midsize businesses, and national and international clients across a broad range of industries. Whitney develops legal strategies aligned with each client’s business objectives and helps clients navigate complex disputes efficiently.

Whitney represents clients in the health care, pharmaceutical and life sciences, manufacturing, transportation, and technology sectors. Her experience includes defeating a billion-dollar claim in a six-week antitrust trial; securing affirmance by the U.S. Court of Appeals for the Third Circuit of the dismissal with prejudice of a securities class action against a pharmaceutical company; reaching a favorable settlement for a private equity fund manager in a fee dispute with a global placement agent; handling petitions to vacate and confirm arbitration awards, as well as motions to compel arbitration; and managing cross-border arbitrations involving trade secrets, M&A disputes, and joint ventures for clients in the U.S., Europe, and Asia.

In addition to her litigation and arbitration work, Whitney contributes to the firm’s internal initiatives, including serving on Troutman Pepper Locke’s Technology Committee. In this role, she supports the firm’s commitment to using technology to deliver efficient, forward-looking legal services to clients.

Commercial Litigation

• Obtained a complete defense verdict in a six-week antitrust trial on behalf of two egg producer cooperatives alleged to have orchestrated an industry-wide supply restriction scheme to fix the prices of eggs and egg products sold in the U.S. Damages were claimed to be in excess of $1 billion. Representation also included acting in capacity of liaison defense counsel.
• Represented a pharmaceutical company in a securities class action litigation in the Eastern District of Pennsylvania involving alleged disclosures made in connection with the company’s efforts to gain FDA approval of a COVID-19 vaccine, and related derivative litigation. Obtained a complete dismissal with prejudice, which was affirmed by the Third Circuit. In re Ocugen, Inc. Sec. Litig., 659 F. Supp. 3d 572 (E.D. Pa. Mar. 3, 2023), aff’d 2024 WL 1209513 (3d Cir. Mar. 21, 2024).
• Representing a pharmaceutical company and its officers in a class action involving claims brought under the Securities Exchange Act of 1934 and Rule 10b-5, and in related derivative litigations.
• Obtained a favorable settlement on behalf of a biopharmaceutical company in a litigation brought by a former officer relating to the exercise of stock options.
• Representing a leading U.S. health care provider in multiple payment disputes with payors and joint venture partners.
• Represented a service provider to health care facilities and its officers in a class action involving claims brought under the Securities Exchange Act of 1934 and Rule 10b-5, and in related derivative litigations.
• Supervising complex civil litigation in India involving a French client company, its Dutch subsidiary, and their Indian joint venture partner in an appeal to the Indian Supreme Court.
• Represented a leading metal processor and distributor in a breach of contract and warranty dispute.
• Represented a large regional railroad company in a variety of contract disputes and other matters.
• Obtained injunctive relief and a favorable settlement on behalf of a French company in an action against a former employee for fraud and breach of contract.
• Obtained a favorable settlement on behalf of a private equity fund manager in a fee dispute with a global placement agent.
• Obtained a favorable settlement on behalf of a security and fire protection company in a case involving breach of a software license agreement.
• Obtained a favorable settlement on behalf of a French transformer manufacturer in a breach of warranty dispute.

Arbitration

• Prevailed on a motion to stay litigation in favor of international arbitration in a high stakes dispute between a manufacturer and distributor in the U.S. District Court for the Northern District of Texas.
• Representing a Japanese life sciences company in an ICC expedited arbitration involving a trade secret dispute.
• Represented an Indian manufacturing company and its U.S. subsidiary in an ICC arbitration involving breaches of representations and warranties in a membership interest purchase agreement.
• Obtained a complete defense award, and prevailed in part on counterclaims, in a five-day AAA construction dispute relating to the integration of two technologies.
• Obtained a complete defense award, and prevailed in part on counterclaims, in a seven-day JAMS arbitration between a U.K. pharmaceutical manufacturer and its licensee regarding the interpretation of the license agreement.
• Represented a major medical device company in an eight-day AAA arbitration involving a multimillion-dollar indemnification claim.
• Obtained a significant quantum award for client in an LCIA international arbitration involving an Indian real estate joint venture.
• Represented a large health care provider in AHLA arbitrations involving payment disputes with payors and contract negotiators.

• Best Lawyers in America®: Ones to Watch: Commercial Litigation (2024-2025)